First-in-Human Study of RGT-419B Alone and With Endocrine Therapy in Subjects With HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
Condition: Breast Cancer Interventions: Drug: RGT-419B; Drug: RGT-419B in combination with hormonal therapy Sponsor: Regor Pharmaceuticals Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | HER2 | Hormonal Therapy | Hormones | Research | Study